Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 4 de 4
Filtrar
Adicionar filtros








Intervalo de ano
1.
Acta cir. bras ; 34(2): e201900201, 2019. graf
Artigo em Inglês | LILACS | ID: biblio-989059

RESUMO

Abstract Purpose: To investigated the effects of ginsenoside Rb1 on diabetic retinopathy in streptozotocin-induced diabetic rats. Methods: Diabetes was induced by a single intraperitoneal injection of streptozotocin (80 mg/kg) in male Wistar rats. Ginsenoside Rb1 (20, 40 mg/kg) was injected (i.p.) once a day for 4 weeks. Then, using fundus photography, the diameter and vascular permeability of retinal vessels were investigated. Retinal histopathology was undertaken. Contents of malondialdehyde (MDA) and glutathione (GSH) in retinas were assayed. Levels of nuclear factor erythroid 2-related factor 2 (Nrf2), glutathione cysteine ligase catalytic subunit (GCLC), and glutathione cysteine ligase modulatory subunit (GCLM) were measured. Results: Treatment with ginsenoside Rb1 attenuated the diabetes-induced increase in the diameter of retinal blood vessels. Ginsenoside Rb1 reduced extravasation of Evans Blue dye from retinal blood vessels. Ginsenoside Rb1 partially inhibited the increase in MDA content and decrease in GSH level in rat retinas. Nrf2 levels in the nuclei of retinal cells and expression of GCLC and GCLM were increased significantly in rats treated with ginsenoside Rb1. Conclusion: These findings suggest that ginsenoside Rb1 can attenuate diabetic retinopathy by regulating the antioxidative function in rat retinas.


Assuntos
Animais , Masculino , Ratos , Diabetes Mellitus Experimental/tratamento farmacológico , Retinopatia Diabética/tratamento farmacológico , Vasos Retinianos/efeitos dos fármacos , Vasos Retinianos/patologia , Ratos Wistar , Estreptozocina , Ginsenosídeos/uso terapêutico
2.
Indian J Ophthalmol ; 2011 Jan; 59(1): 51-53
Artigo em Inglês | IMSEAR | ID: sea-136139

RESUMO

A 48-year-old man presented following an episode of sudden onset simultaneous inferior altitudinal visual loss in his left eye and visual obscuration with shimmering in the inferonasal quadrant of the right eye. Clinical examination demonstrated left superior hemiretinal artery occlusion and an area of focal dynamic spasm along the right superior temporal branch retinal artery, the arteriolar spastic cycle was about 2 sec in duration. Hematological (including complete blood count, thrombophilia screen, vasculitic screen and serum magnesium), carotid, and cardiac investigations were normal. He was given acetazolamide 500 mg orally, timolol maleate 0.5% eye drops once daily and sublingual amyl-nitrate 0.8 mg, and maintained on felodipine 10 mg/day and aspirin 100 mg/day. The area of focal arteriolar spasm in the right eye resolved over two months. To our knowledge there are no prior reports of photographically documented dynamic focal retinal vascular spasm on a MEDLINE and PUBMED search.


Assuntos
Arteríolas/efeitos dos fármacos , Arteríolas/patologia , Esquema de Medicação , Seguimentos , Fundo de Olho , Humanos , Masculino , Pessoa de Meia-Idade , Transtornos de Enxaqueca/complicações , Transtornos de Enxaqueca/fisiopatologia , Fotografação , Oclusão da Artéria Retiniana/etiologia , Oclusão da Artéria Retiniana/patologia , Vasos Retinianos/efeitos dos fármacos , Vasos Retinianos/patologia , Vasoconstrição/efeitos dos fármacos , Vasodilatadores/administração & dosagem
3.
Yonsei Medical Journal ; : 325-327, 2007.
Artigo em Inglês | WPRIM | ID: wpr-22294

RESUMO

Photodynamic therapy (PDT) involves the induction of endothelial cell death or occlusion of blood vessels. On the basis of this mechanism of action, PDT is used in the treatment of predominant classic choroidal neovascularization (CNV), if the classic component is over 50%, and in myopic CNV. This study describes 2 cases of distinctive, abnormal, large, subretinal new vessels that are thought to have originated from the choroids. Diminishment of the new vessels was observed following treatment with PDT.


Assuntos
Pessoa de Meia-Idade , Masculino , Humanos , Feminino , Vasos Retinianos/efeitos dos fármacos , Doenças Retinianas/tratamento farmacológico , Fotoquimioterapia , Neovascularização Patológica/tratamento farmacológico , Angiografia
4.
Arq. bras. oftalmol ; 69(6): 941-944, nov.-dez. 2006. ilus
Artigo em Português | LILACS | ID: lil-440438

RESUMO

Relato de caso de um paciente com telangiectasia justafoveal idiopática (TJI) tipo 1A, no olho direito, submetido a 4 mg de triancinolona intravítrea. O resultado foi avaliado por meio da acuidade visual e da tomografia de coerência óptica. A acuidade visual e a espessura retiniana macular medida na tomografia de coerência óptica, antes da injeção intravítrea de triancinolona, foram respectivamente de 20/100 e 569 æm e, após três semanas do tratamento foram de 20/60 e 371 æm e na sexta semana de 20/100 e 614 æm. A estabilização da parede vascular obtida com injeção intravítrea de triancinolona proporciona melhora transitória da visão e do edema macular em olhos com TJI-1A. Não foi demonstrada nenhuma ajuda permanente à fotocoagulação prévia.


Case report of one idiopathic juxtafoveal telangiectasis (IJT) 1A patient whose right eye was treated with a 4 mg intravitreal triamcinolone acetonide injection. The outcome was evaluated by visual acuity and optic coherence tomography. The visual acuity and the caliper retinal thickness before triamcinolone injection were respectively 20/100 and 569 æm, and 20/60 and 371 æm after three weeks and 20/100 and 614 æm after six week of follow-up. The stabilization of the vascular wall due to the intravitreal triamcinolone injection leads to a transitory improvement in vision and reduction in macular edema in the TJI 1A eyes. No permanent help by the photocoagulation could be shown.


Assuntos
Humanos , Masculino , Pessoa de Meia-Idade , Glucocorticoides/administração & dosagem , Doenças Retinianas/tratamento farmacológico , Vasos Retinianos/efeitos dos fármacos , Telangiectasia/terapia , Triancinolona Acetonida/administração & dosagem , Injeções , Edema Macular/tratamento farmacológico , Vasos Retinianos/patologia , Fatores de Tempo , Acuidade Visual , Corpo Vítreo/efeitos dos fármacos
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA